Articles tagged “Epitalon”
4 articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 to evaluate 7 peptide compounds for 503A inclusion. Here's what they decided and what it means for patients, clinics, and the compounding industry.
What Is Epitalon? Mechanism, Uses, Risks, and FDA Status
An evidence-based overview of Epitalon (Epithalon) — a synthetic tetrapeptide studied for its potential to activate telomerase, extend telomere length, and modulate aging-related biomarkers.
The July 2026 PCAC Meeting: What's at Stake for BPC-157, TB-500, Semax, and More
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee will decide whether seven peptides — including BPC-157 and TB-500 — get formally authorized for compounding. Here's what the process looks like, what outcomes are possible, and what it means for patients and clinicians.
FDA Removes 12 Peptides from Category 2: What It Actually Means
On April 15, 2026, the FDA announced that 12 peptides — including BPC-157, TB-500, Semax, and Epitalon — will exit the Category 2 restricted list on April 22. Here's a clear breakdown of what changed, what didn't, and what happens next.